TriangleNCT00142168 · OUTCOME
Time to Progression
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- Full Range
- Time frame
- 34.3 months
What was measured
Time to progression is measured as the length in time in months from starting therapy until progression, defined as 25% increase in serum IgM from nadir.
Analysis population: All enrolled patients
Groups in this outcome
Lenalidomide and Rituximab
Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
| Group | Source count |
|---|---|
| Lenalidomide and Rituximab | 16 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Lenalidomide and Rituximab | 17.1 | Not reported | 2 | 34.3 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 2
- upper Limit
- 34.3
- value
- 17.1
- denoms
- counts
- group Id
- OG000
- value
- 16
- units
- Participants
- description
- Time to progression is measured as the length in time in months from starting therapy until progression, defined as 25% increase in serum IgM from nadir.
- dispersion Type
- Full Range
- groups
- description
- Intended therapy consisted of 48 weeks of lenalidomide (25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.
- id
- OG000
- title
- Lenalidomide and Rituximab
- param Type
- MEDIAN
- population Description
- All enrolled patients
- reporting Status
- POSTED
- time Frame
- 34.3 months
- title
- Time to Progression
- type
- PRIMARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice